Navigation Links
Novelos Therapeutics Prices $5.5 Million Public Offering
Date:2/13/2013

MADISON, Wis., Feb. 13, 2013 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced the pricing of a public offering of 11,000,000 units at $0.50 per unit for gross proceeds of $5,500,000.  Each unit consists of one share of our common stock, a Class A Warrant with a one-year term to purchase one-half of a share of our common stock at an exercise price of $0.50 per share and a Class B Warrant with a five-year term to purchase one share of our common stock at an exercise price of $0.50 per share.  Novelos expects to close the transaction, subject to customary conditions, on or about February 19, 2013.

Burrill Securities LLC is acting as a placement agent in a co-lead capacity for the offering.  Dawson James Securities, Inc. is acting as a sub-agent in a co-lead capacity.

The Benchmark Company, LLC is acting as a sub-agent.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer or sale of these securities in any jurisdiction or to any person in any particular jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The offering will be made only by means of a prospectus supplement and accompanying prospectus, copies of which may be obtained from Burrill Securities LLC, Prospectus Department, One Embarcadero Center, Suite 2700, San Francisco, CA 94111, 415-591-5400 or email: ksheinerman@b-c.com.  Before any investment, an investor should read the prospectus supplement and the accompanying prospectus, including the information incorporated by reference therein, for more complete information about Novelos and this offering.

INVESTOR CONTACTS
J. Patrick Genn , Vice President of IR, Novelos Therapeutics, Inc., Madison, Wisc. & Boston, Mass., Ph: (858) 775-7456, Email: jpgenn@novelos.com

Anne Marie Fields , Senior Vice President, LHA, Ph: (212) 838-3777, Email: afields@lhai.com, @LHA_IR_PR

This news release contains forward-looking statements.  You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates.  Such statements are valid only as of today, and we disclaim any obligation to update this information.  These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.  These statements are based on our current beliefs and expectations as to such future outcomes.  Drug discovery and development involve a high degree of risk.  Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our  pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.


'/>"/>
SOURCE Novelos Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Novelos Therapeutics To Present At The 15th Annual BIO CEO & Investor Conference On February 11
2. Novelos Therapeutics Presents Diapeutic Technology Platform At EMIT: Targeted Radiotherapy International Conference
3. Novelos Therapeutics To Present At The Benchmark 2012 Micro Cap Discovery Investor Conference On November 29
4. Novelos Therapeutics Closes $2 Million Private Placement
5. Novelos Therapeutics Announces Enrollment of First Patient in Solid Tumor Imaging Trial with I-124-CLR1404 (LIGHT) Cancer-targeted PET Imaging Agent at UW Carbone Cancer Center
6. Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
7. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
8. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
9. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
10. Novelos Therapeutics Prices $5.4 Million Public Offering
11. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2020)... ... January 09, 2020 , ... R3 Stem Cell, the ... freezer program. The cryogenic freezer allows practices to have plenty of stem cell ... exosome biologics require cryogenic freezing. This may include a practice receiving the biologics ...
(Date:1/7/2020)... ... January 07, 2020 , ... Ironsphere, ... service providers, announced today it has been selected by MetLife Stadium for Privileged ... , “As part of our ongoing commitment to maintain the highest of security ...
(Date:1/7/2020)... TORONTO (PRWEB) , ... January 06, 2020 , ... Myant ... that enable continuous and ambient heart health management at CES 2020 (January 7-10, Las ... as a winner in the Health & Wellness category of the CES 2020 Innovation ...
Breaking Medicine Technology:
(Date:1/23/2020)... ... January 23, 2020 , ... DelawareBio, a nonprofit trade ... a panel discussion on gene editing that goes beyond CRISPR technology. To be ... Education Center, the event will provide an overview of the opportunities and challenges ...
(Date:1/23/2020)... ... January 23, 2020 , ... Three leading healthcare organizations, ... to improve diagnostic quality and safety by joining the Coalition to Improve ... healthcare and patient advocacy. , “Diagnostic error is one of the most important ...
(Date:1/23/2020)... (PRWEB) , ... January 23, 2020 , ... ... and risk services for organizations that operate vehicle fleets in North America and ... subscriber-based e-newsletter, will be published monthly with content accessible on the company’s website. ...
(Date:1/23/2020)... Texas (PRWEB) , ... January 23, 2020 , ... ... announced a strategic partnership using SocialClimb’s innovative technology to power the Arrowlytics platform ... practice efficiency and profitability. SocialClimb’s platform integrates seamlessly with practice management systems to ...
(Date:1/22/2020)... (PRWEB) , ... January 22, ... ... cloud-based ambulatory EHR , revenue cycle management services, integrated practice management, ... System, Hospital Information Management System and Personal Health Record for Indian healthcare ...
Breaking Medicine News(10 mins):